BiotechTube
NeuraSignal

NeuraSignal

Houston, United States· Est.
neurasignal.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

NeuraSignal is a commercial-stage medical device company revolutionizing neurovascular monitoring through its autonomous, robotic TCD ultrasound platform. Its flagship NG2 system leverages AI and robotics to automate the technically challenging process of obtaining cerebral blood flow signals, aiming to improve diagnostic accuracy, standardization, and accessibility of TCD exams. The company is initially focused on the stroke care market, with strong clinical evidence demonstrating superior patent foramen ovale (PFO) detection rates compared to traditional echocardiography. By providing real-time, bedside hemodynamic data, NeuraSignal seeks to improve clinical decision-making, reduce hospital costs, and enhance patient outcomes in neurology and critical care.

StrokeNeurovascular Disorders

Technology Platform

AI-powered robotic Transcranial Doppler (TCD) ultrasound system that automates cerebral blood flow signal acquisition and analysis.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The large and growing global stroke burden, coupled with the clinical shift towards PFO closure for secondary prevention, creates a significant market for high-sensitivity screening tools.
The platform's software nature allows for expansion into new diagnostic applications and predictive analytics in neurology, moving beyond a device into a comprehensive brain health data platform.

Risk Factors

Market adoption faces hurdles from entrenched hospital protocols and reimbursement challenges.
Competition from large ultrasound incumbents developing automation features poses a long-term threat.
As a young company, execution risks in scaling commercial operations, manufacturing, and continuous R&D are present.

Competitive Landscape

NeuraSignal competes with traditional manual TCD systems from companies like Natus and Rimed, and indirectly with transthoracic echocardiography (TTE) for PFO detection. Its primary differentiation is full robotic automation and AI-enhanced analysis. Potential future competitors include major ultrasound giants (Philips, GE, Siemens) if they introduce similar automated TCD capabilities.

More companies in Neuroscience & CNS →More companies in United States →